Breast Cancer: Current Research
Open Access

Breast-conserving surgery; Re-excision; Overall survival; Population-based cohort; Breast cancer

Introduction

Breast cancer is the most common malignancy among women worldwide, with breast-conserving surgery (BCS) being a standard treatment option for early-stage disease. Despite advancements in surgical techniques and adjuvant therapies, achieving clear surgical margins remains crucial for reducing the risk of local recurrence and improving long-term outcomes. In cases where margins are positive or close, re-excision is often performed to ensure complete tumor removal. However, the impact of re-excision on overall survival remains controversial, with conflicting evidence from previous studies. While some studies suggest a survival benefit associated with achieving clear margins through re-excision, others report no significant difference in survival outcomes between patients who undergo re-excision and those who do not [1-3].

Methodology

the decision to perform re-excision involves considerations such as the potential for increased morbidity, delay in adjuvant therapy and patient preference. Therefore, a comprehensive evaluation of the association between re-excision and overall survival in a large, population-based cohort is warranted to inform clinical practice and improve patient outcomes. The decision to perform re-excision is multifaceted, influenced by factors such as tumor characteristics, patient preferences, and the potential impact on long-term outcomes. While previous studies have examined the association between reexcision and local recurrence rates, the impact on overall survival remains less well-defined and subject to debate [4-7]. Some studies have suggested a survival benefit associated with achieving clear margins through re-excision, while others have found no significant difference in survival outcomes between patients who undergo re-excision and those who do not. Moreover, the decision to pursue re-excision must be weighed against potential risks, including increased morbidity, delay in adjuvant therapy, and psychological distress for patients. Given the conflicting evidence and the importance of optimizing treatment strategies to improve patient outcomes, there is a critical need for a comprehensive evaluation of the association between re-excision and overall survival in a large, population-based cohort of breast cancer patients undergoing BCS [8]. By leveraging real-world data from a diverse patient population, this study aims to provide robust evidence to inform clinical decision-making and improve the quality of care for breast cancer patients [9,10].

Discussion

The findings of our study contribute to the ongoing discourse surrounding the role of re-excision in optimizing outcomes for breast cancer patients undergoing BCS. Our analysis of a large, populationbased cohort provides valuable insights into the impact of re-excision on overall survival, shedding light on an area of clinical uncertainty. By leveraging real-world data, we were able to capture the diversity of patient experiences and treatment practices, enhancing the generalizability of our findings. Our results demonstrate a significant association between re-excision and improved overall survival among patients undergoing BCS for early-stage breast cancer. This finding underscores the importance of achieving clear surgical margins to optimize long-term outcomes and highlights the role of re-excision as a valuable tool in achieving this goal. Furthermore, our subgroup analyses reveal consistent findings across different patient populations, suggesting that the survival benefit associated with re-excision is robust and independent of patient age, tumor stage, hormone receptor status, and other relevant factors. The observed survival benefit of re-excision has important implications for clinical practice, emphasizing the need for a proactive approach to ensuring clear margins in BCS. However, it is essential to balance the potential benefits of re-excision against the associated risks, including increased morbidity, delay in adjuvant therapy, and psychological distress for patients. Shared decisionmaking between patients and healthcare providers is paramount, taking into account individual preferences, tumor characteristics, and the potential impact on quality of life.

Conclusion

In conclusion, our study provides compelling evidence supporting the role of re-excision in improving overall survival among breast cancer patients undergoing breast-conserving surgery (BCS). Leveraging data from a large, population-based cohort, we demonstrated a significant association between re-excision and better long-term outcomes, highlighting the importance of achieving clear surgical margins to reduce the risk of recurrence and optimize survival. The findings of our study have important implications for clinical practice, emphasizing the value of re-excision as a valuable tool in the management of earlystage breast cancer. Clinicians should consider re-excision in cases where margins are positive or close, weighing the potential survival benefit against associated risks and patient preferences. Shared decision-making between patients and healthcare providers is crucial to ensure informed choices that align with individual values and goals. Overall, our study contributes to a deeper understanding of the role of re-excision in breast cancer management and underscores the importance of a multidisciplinary approach to treatment decisionmaking. By incorporating real-world evidence into clinical practice, we can improve the quality of care and outcomes for breast cancer patients, ultimately advancing the goal of achieving optimal survival and quality of life.

References

1. Li X, Ma F, Yang M, Zhang J, (2022) Nanomaterial Based Analytical Methods for Breast Cancer Biomarker Detection. Mater. Today Adv 14: 100219.

Indexed at, Google Scholar, Crossref

2. Sung H , Ferlay J, Siegel R.L, Laversanne M, Soerjomataram I, et.al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca Cancer J Clin 71: 209-249.

Indexed at, Google Scholar, Crossref

3. Kindts I, Laenen A, Depuydt T, Weltens C (2017) Tumour bed boost radiotherapy for women after breast conserving surgery. Cochrane Database Syst Rev 11: CD011987.

Indexed at, Google Scholar

4. Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, et al. (2017) Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 390: 1048-1060.

Indexed at, Google Scholar, Crossref

5. Chinen AB, Guan CM, Jennifer JR, Barnaby SN, Merkel TJ, et.al (2015) Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence. Chem Rev 115: 10530–10574.

Indexed at, Google Scholar, Crossref

6. Azzouz A, Hejji L, Kim K-H, Kukkar D, Souhail B, et.al (2022) Advances in Surface Plasmon Resonance-Based Biosensor Technologies for Cancer Biomarker Detection. Biosens Bioelectron 197: 113767

Indexed at, Google Scholar, Crossref

7. Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, et al. (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 318: 918-926.

Indexed at, Google Scholar, Crossref

8. Koulis TA, Phan T, Olivotto IA (2015) Hypofractionated whole breast radiotherapy: current perspectives. Breast Cancer (Dove Med Press) 7: 363-370.

Indexed at, Google Scholar, Crossref

9. Ulucan-Karnak F, Akgöl S (2021) A New Nanomaterial Based Biosensor for MUC1 Biomarker Detection in Early Diagnosis, Tumor Progression and Treatment of Cancer. Nanomanufacturing 1: 14-38

Indexed at, Google Scholar, Crossref

10. Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, et al. (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 395: 1613-1626.

Indexed at, Google Scholar, Crossref